First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours

Oral perifosine was tolerable up to 600 mg/week in cancer patients when administered with meal and prophylactic antiemetics. Based on its half-life of about 4 days, a weekly regimen may be appropriate.